Under the agreement, Twist Biopharma, a division of Twist Bioscience, will grant access to Pure Biologics to select synthetic antibody phage display libraries derived from sequences that exist only in the human body and that are optimized using artificial intelligence and big data analytics.

The companies will work together to develop new antibody candidates that are useful for immuno-oncology therapies. Certain libraries are tailored deliberately to match chosen classes of biological targets.

Pure Biologics will pay Twist technology access fees annually, as well as future payments for preclinical, clinical, and commercial achievement for any antibodies resulting from the deal.

Twist Bioscience purchases library designed with Distributed Bio
Twist Bioscience plans to exercise its option to purchase all rights to a G-coupled protein receptor library and its Twist antibody optimization software,...

Stanford gains access to Twist's 'library of libraries'
Twist Bioscience has granted Stanford University access to its antibody discovery and optimization services and its "library of libraries" for biologics...

Twist Bioscience inks agreements for antibody therapeutic discovery
Twist Bioscience said that its Twist Biopharma division has signed licensing deals with Serotiny and Applied StemCell aimed at discovering new antibody...

Twist to offer RNA control for U.K. strain of SARS-CoV-2
Twist Bioscience plans to offer a new synthetic RNA control that includes the new variant of SARS-CoV-2 circulating in the U.K. and South Africa.

Twist Bioscience touts positive preclinical data for SARS-CoV-2 antibodies
Twist Bioscience has touted preclinical results for three of its proprietary antibodies against the novel coronavirus S1 subunit protein.